These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 31134501)

  • 21. Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
    Copland M; Jørgensen HG; Holyoake TL
    Hematology; 2005 Oct; 10(5):349-59. PubMed ID: 16203604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells.
    Allan EK; Holyoake TL; Craig AR; Jørgensen HG
    Leukemia; 2011 Jun; 25(6):985-94. PubMed ID: 21468038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discontinuation of TKI therapy and 'functional' cure for CML.
    Mahon FX
    Best Pract Res Clin Haematol; 2016 Sep; 29(3):308-313. PubMed ID: 27839571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The next questions in chronic myeloid leukaemia and their answers.
    Marin D; Rotolo A; Milojkovic D; Goldman J
    Curr Opin Hematol; 2013 Mar; 20(2):163-8. PubMed ID: 23334193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
    Luu MH; Press RD
    Expert Rev Mol Diagn; 2013 Sep; 13(7):749-62. PubMed ID: 24063401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.
    Zhang B; Li L; Ho Y; Li M; Marcucci G; Tong W; Bhatia R
    J Clin Invest; 2016 Mar; 126(3):975-91. PubMed ID: 26878174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
    Wang J; Hu J; Jin Z; Wan H
    Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.
    Koschmieder S; Vetrie D
    Semin Cancer Biol; 2018 Aug; 51():180-197. PubMed ID: 28778403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of Chronic Myeloid Leukemia in Mice.
    Zhang H; Li S
    Methods Mol Biol; 2016; 1465():17-25. PubMed ID: 27581135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cure of Chronic Myeloid Leukemia: Are We There Yet?
    Saikia T
    Curr Oncol Rep; 2018 Feb; 20(2):12. PubMed ID: 29492683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The molecular biology of chronic myeloid leukaemia.
    Melo JV
    Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.